Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-19
2005-04-19
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S079000
Reexamination Certificate
active
06881732
ABSTRACT:
Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.
REFERENCES:
patent: 5380515 (1995-01-01), Winchell et al.
patent: 5854287 (1998-12-01), Weglicki
patent: 5874573 (1999-02-01), Winchell et al.
patent: 6264966 (2001-07-01), Winchell et al.
patent: 20010033854 (2001-10-01), Johnson et al.
patent: 20010036964 (2001-11-01), Clarkson et al.
The Merck Manual of Diagnosis and Therapy, 14thed. , (1982), pp 910-915.*
Blot, W.J., et al., “Nutrition Intervention Trials in Linxian, China: Supplementation with Specific Vitamin/Mineral Combinations, Cancer Incidence, and Diseaese-Specific Mortality in the General Population,”Journal of the National Cancer Institute, 1993, pp. 1483-1492, vol. 85, No. 18.
Omenn, G.S., et al., “Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease,”New England Journal of Medicine, 1996, pp. 1150-1155, vol. 334, No. 18.
Hennekens, C.H., et al., “Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease,” New England Journal of Medicine, 1996, pp. 1145-1149, vol. 334, No. 18.
Grennberg, E.R., et al., “Mortality Associated with Low Plasma Concentration of Beta Carotene and the Effect ofOral Supplementation,”JAMA, 1996, pp. 699-703, vol. 275, No. 9.
Gilgun-Sherkl, Y., et al., “Antioxidant Therapy in Acute Central Nervous System Injury: Current State,”; 2002,Pharm. Rev. vol. 54, pp. 271-284.
Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomized placebo-controlled trial,”; 2002,The Lancetvol. 360, pp. 23-33.
Chelator LLC
Concat, Ltd.
Heines M. Henry
Henley III Raymond J.
Townsend and Townsend / and Crew LLP
LandOfFree
Neuroprotection and cardioprotection afforded by chelators... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotection and cardioprotection afforded by chelators..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotection and cardioprotection afforded by chelators... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377753